A Phase 3 interventional study of Adalimumab in Crohn's Disease, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-11-14.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.
Among the 42 studies testing adalimumab in Crohn Disease, this one is the 10th largest by enrollment, is one of 4 that started in 2014, is one of 22 in phase 3, and was the 28th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 6–17
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18–70
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 24 · Phase 4 13
First in 2002; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 143 across the 42 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 42 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
55 studies in Crohn Disease by AbbVie: 6 open now, 14 under way, 6 of them phase 3. Of 38 finished, 28 (74%) have results posted.
Among the 55 studies in Crohn Disease by AbbVie, this one is the 12th largest by enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2014, is one of 16 in phase 3, and was the 19th registered.
AbbVie’s Crohn Disease studies by the year they started, since 2007.
1 of the studies testing adalimumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing adalimumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in participants with Crohn's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received open-label adalimumab 40 mg by subcutaneous injection every other week for 40 weeks.
Drug: Adalimumab
Adalimumab pre-filled syringe, administered by subcutaneous injection
Also known as: Humira, ABT-D2E7
Percentage of Participants With Endoscopic Improvement at Week 40 in Participants With Endoscopic Improvement at Week 0
Endoscopic improvement defined as a simple endoscopic score for Crohn's Disease (SES-CD) score of ≤4 and at least a 2-point reduction compared with Study M14-115 (NCT02185014) Baseline and no subscore greater than 1 in any individual endoscopic variable. The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The Total Score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 40
| Milestone | Adalimumab |
|---|---|
| Started | 252 |
| Completed | 198 |
| Not completed | 54 |
| Withdrew: Adverse event | 18 |
| Withdrew: Withdrew consent | 8 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Lack of efficacy | 14 |
| Withdrew: Requires alternative/prohibited therapy | 5 |
| Withdrew: Subject noncompliance | 1 |
| Withdrew: Other | 4 |
Endoscopic improvement defined as a simple endoscopic score for Crohn's Disease (SES-CD) score of ≤4 and at least a 2-point reduction compared with Study M14-115 (NCT02185014) Baseline and no subscore greater than 1 in any individual endoscopic variable. The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The Total Score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Adalimumab |
|---|---|
| Percentage of Participants With Endoscopic Improvement at Week 40 in Participants With Endoscopic Improvement at Week 0 | 31.6 (21.1 to 42.0) |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 48 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab | 0/252 (0%) | 27/252 (10.7%) | 63/252 (25%) |
| Event | Adalimumab |
|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 14/252 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 4/252 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 3/252 |
| ANAL ABSCESSInfections and infestations | 3/252 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 1/252 |
| ILEAL STENOSISGastrointestinal disorders | 1/252 |
| NON-CARDIAC CHEST PAINGeneral disorders | 1/252 |
| POST PROCEDURAL HAEMORRHAGEInjury, poisoning and procedural complications | 1/252 |
| INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders | 1/252 |
| HEADACHENervous system disorders | 1/252 |
| Event | Adalimumab |
|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 30/252 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 18/252 |
| NAUSEAGastrointestinal disorders | 15/252 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 13/252 |
Baseline characteristics from lead-in study M14-115 (NCT02185014)
| Age, Continuous(years) | Adalimumab |
|---|---|
| Mean | 37.5 ± 12.71 |
| Sex: Female, Male(Participants) | Adalimumab |
|---|---|
| Female | 139 |
| Male | 113 |
| Ethnicity (NIH/OMB)(Participants) | Adalimumab |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 245 |
| Race (NIH/OMB)(Participants) | Adalimumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 10 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 12 |
| White | 229 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Simplified endoscopic score for crohn's disease (SES-CD)(units on a scale) | Adalimumab |
|---|---|
| Mean | 14.2 ± 6.74 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Aug 2014, a primary completion of Nov 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab